Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126231 | 0.82 | DGAT1 (0.38) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL8737769 | 0.81 | HDAC6 (0.39) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL901583 | 0.80 | HDAC6 (0.34) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL22143232 | 0.78 | HDAC6 (0.33) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL432112 | 0.77 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL9873641 | 0.75 | HDAC6 (0.36) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL8098483 | 0.75 | HDAC6 (0.40) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL28676568 | 0.75 | HDAC6 (0.36) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| Hydrochloric Acid SCHEMBL5679482 | 0.75 | HDAC6 (0.36) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL4449246 | 0.74 | HDAC6 (0.33) | HDAC6HDAC1HDAC2DGAT1CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653681-B2 | Analgesic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190111031-A1 | ANALGESIC COMPOUNDS | KTHERA, LLC | 2019-04-18 | — | — | US | disclosed |
| WO-2017160922-A1 | ANALGESIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| EP-2097387-B1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2485590-B1 | PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8829036-B2 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8778980-B2 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| CN-101715442-B | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME | 2014-03-26 | — | — | CN | disclosed |
| US-8557826-B2 | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| EP-2007396-B1 | Enfumafungin derivatives as antifungal agents | MERCK SHARP & DOHME (US) | 2013-02-13 | — | — | EP | disclosed |
| US-6963000-B2 | Benzothiazole derivatives with activity as adenosine receptor ligands | HOFFMAN-LA ROCHE INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050026906-A1 | Benzothiazole derivatives with actitvity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2005-02-03 | — | — | US | disclosed |
| US-6835732-B2 | Modulation of the adenosine A2A receptor; cardioprotective agents; antiischemic agents; antihypoxia agents; central nervous system disorders, Alzheimer's disease, Parkinson's disease, anxiolytic agents; antidepressants; analgesics | HOFFMAN-LA ROCHE INC. | 2004-12-28 | — | — | US | disclosed |
| US-20030176695-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-09-18 | — | — | US | disclosed |
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER (FR) | 2003-07-03 | — | — | US | disclosed |
| EP-1303272-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6521754-B2 | Such as N-4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isoni cotinamide | HOFFMAN-LA ROCHE INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | disclosed |
| CN-87102765-A | The preparation method of sweeting agent N-guanidines guanidine-acetic acid and N-phenyl ethanamidine guanidine-acetic acid derivative and the prescription of this class sweeting agent | — | 1987-10-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125318-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | HDAC6 2629/4885HDAC1 2504/4885HDAC2 3092/4885 |
| US-20030176695-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | HDAC6 2629/4885HDAC1 2504/4885HDAC2 3092/4885 |
| US-20050026906-A1 | Benzothiazole derivatives with actitvity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | HDAC6 3101/4885HDAC1 4200/4885HDAC2 3981/4885 |
| US-20190111031-A1 | ANALGESIC COMPOUNDS | OPRK1, OPRL1, OPRM1 | HDAC6 834/4885HDAC1 1488/4885HDAC2 2244/4885 |
| US-20020045615-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | HDAC6 2629/4885HDAC1 2504/4885HDAC2 3092/4885 |
| US-10653681-B2 | Analgesic compounds | OPRK1, OPRL1, OPRM1 | HDAC6 834/4885HDAC1 1488/4885HDAC2 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.